- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1749 |
Product Name |
ADT1749-Human Anti-CD3ExCD20 Bispecific Antibody |
Isotype |
Human IgG4-kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3E mAb, Anti-CD3E Monoclonal Antibody, CD3E recombinant antibody, Anti-CD3E Bispecific Antibody, Human Anti-CD20 mAb, CD20 recombinant antibody, Anti-CD20 Monoclonal Antibody, Anti-CD20 Bispecific Antibody |
|
Official Symbol |
CD3ExCD20 |
Target 1 |
CD3E |
Gene ID 1 |
916 |
Target 2 |
CD20 |
Gene ID 2 |
931 |
Species |
Human |
Drug Name |
Odronextamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
1801338-64-6 |
Product Description |
Odronextamab is a CD20xCD3 bispecific antibody used to treat relapsed/refractory B-Cell non-Hodgkin lymphoma. |
Mechanism of Action |
Odronextamab is a CD20×CD3 bispecific antibody that binds to the CD20 antigen present on the surface of lymphoid cells and the CD3 antigen on CD3-positive effector T-cells. By engaging both targets, odronextamab induces targeted B-cell lysis and cell death. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Tun AM, Ansell SM: Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treat Rev. 2020 Aug;88:102042. doi: 10.1016/j.ctrv.2020.102042. Epub 2020 May 30.
2. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chavez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS: Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1.
|
FAQ
-
+ -
What is CD3E’s role?
CD3E is a T-cell co-receptor. Engaging CD3E recruits T-cells to eliminate CD20-expressing B-cell malignancies.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
Why target CD20?
CD20 is a B-cell surface marker overexpressed in lymphomas and leukemias. -
+ -
What are bispecific antibodies (BsAbs)?
A bispecific antibody (BsAb) is an engineered antibody capable of binding two distinct antigens or epitopes simultaneously, enabling novel therapeutic mechanisms not achievable with monoclonal antibodies.